Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
7 participants
OBSERVATIONAL
2012-12-31
2014-04-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
* To measure dopamine receptor occupancy by aripiprazole in patients treated with the antipsychotics
* To validate the simulation result by comparing the receptor occupancy from the simulation with that from the patients
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Change in Brain Metabolism and Cognitive Function by Aripiprazole
NCT01562808
Aripiprazole for Neuroleptic-Induced Tardive Dyskinesia
NCT00837707
Effectiveness of Aripiprazole Long-acting Injection in Recent Onset and Chronic Schizophrenia Patients
NCT03839251
The New Strategy for Pharmacological Treatment in People With Schizophrenia
NCT00352339
Efficacy and Safety of Aripiprazole in First Episode Psychosis
NCT01026584
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_ONLY
CROSS_SECTIONAL
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
aripiprazole
Patient group who is treated with aripiprazole
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* treated with aripiprazole or risperidone
* no change in dose of antipsychotics for at least 6 weeks
* total PANSS score should be below 80
Exclusion Criteria
* history of head trauma
* positive in urine hCG
* on antidepressant, anticholinergics or mood stabilizer
20 Years
55 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Seoul National University Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Jun Soo Kwon
Professor
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Jun Soo Kwon, M.D., Ph.D.
Role: PRINCIPAL_INVESTIGATOR
Seoul National University Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Seoul National University Hospital
Seoul, , South Korea
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
A070001
Identifier Type: OTHER_GRANT
Identifier Source: secondary_id
C-1205-094-410
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.